EUVIMEDEUVIMED entdecken
Crossref

Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer

Zhangyi Luo, Yixian Huang, Shangyu Chen, Bei Zhang, Haozhe Huang, Sheida Dabiri, Yuang Chen, Anju Zhang, Alexis R Andreas, Song Li

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Zhangyi Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Liposomes, Poly(ADP-ribose) Polymerase Inhibitors, Benzimidazoles, DNA Repair. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARP inhibitors (PARPi) benefit only a small subset of patients with DNA homologous recombination (HR) defects. In addition, long-term administration of a PARPi can lead to the development of drug resistance. 2-Hydroxyglutarate (2HG) has long been known as an oncometabolite but is capable of inducing an HR defect, which makes tumor cells exquisitely sensitive to PARPi. To facilitate the translation of this discovery to the treatment of both HR-deficient and HR-proficient tumors, a liposomal formulation was developed for codelivery of 2HG and veliparib, a PARPi. A sequential loading protocol was developed such that the initial loading of 2HG into liposomes greatly facilitated the subsequent, pH gradient-driven remote loading of veliparib. The liposomes co-loaded with veliparib and 2HG exhibited favorable stability, slow kinetics of drug release, and targeted delivery to the tumor. Furthermore, the veliparib/2HG liposomes demonstrated enhanced anti-tumor activity in both PARPi-resistant BRCA mutant cancer and BRCA wildtype cancer by synergistically enhancing the defect in DNA repair. Moreover, combination of veliparib and 2HG via liposomal co-delivery also augmented the function of cytotoxic T cells by activating the STING pathway and downregulating PD-L1 expression via 2HG-induced hypermethylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesPoly(ADP-ribose) Polymerase InhibitorsBenzimidazolesDNA RepairHumansAnimalsCell Line, TumorXenograft Model Antitumor AssaysFemaleMiceDrug SynergismNeoplasmsBRCA1 Protein

Substanzen

LiposomesPoly(ADP-ribose) Polymerase InhibitorsBenzimidazolesveliparibBRCA1 Protein

Autor:innen und Institutionen

  • Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA.
  • Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA. Electronic address: sol4@pitt.edu.

Förderung

  • NIH

Zitieren

APA

Luo, Z., Huang, Y., Chen, S., Zhang, B., Huang, H., Dabiri, S., Chen, Y., Zhang, A., Andreas, A. R., & Li, S. (2024). Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217268

Vancouver

Luo Z, Huang Y, Chen S, Zhang B, Huang H, Dabiri S, et al. Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217268

BibTeX
@article{Luo2024,
  author = {Luo, Zhangyi and Huang, Yixian and Chen, Shangyu and Zhang, Bei and Huang, Haozhe and Dabiri, Sheida and Chen, Yuang and Zhang, Anju and Andreas, Alexis R and Li, Song},
  title = {Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217268}
}
Kostenlos starten →